Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM5 | Q9NZQ8 | 6/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.33 |
| ▸ | SLC10A2 | Q12908 | 5/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17528481 | 0.80 | DRD2 (0.36) | SLC10A2MEN1KMT2A | |
| SCHEMBL9961460 | 0.76 | SLC10A2 (0.48) | SLC10A2 | |
| SCHEMBL1387331 | 0.76 | SLC10A2 (0.48) | SLC10A2 | |
| SCHEMBL18748574 | 0.66 | SLC10A2 (0.58) | SLC10A2 | |
| SCHEMBL7477850 | 0.65 | SLC10A2 (0.38) | SLC10A2 | |
| SCHEMBL8689617 | 0.65 | SLC10A2 (0.42) | SLC10A2 | |
| SCHEMBL8797258 | 0.65 | SLC10A2 (0.42) | SLC10A2 | |
| SCHEMBL7477854 | 0.65 | SLC10A2 (0.38) | SLC10A2 | |
| SCHEMBL9284370 | 0.64 | SLC10A2 (0.44) | SLC10A2 | |
| SCHEMBL22544383 | 0.63 | SLC10A2 (0.50) | SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2968230-A2 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS AND INFLAMMATORY BOWEL DISEASE | Lumena Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2968262-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF BARRETT'S ESOPHAGUS AND GASTROESOPHAGEAL REFLUX DISEASE | Lumena Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2015065983-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF GASTROINTESTINAL INFECTIONS | Lumena Pharmaceuticals, Inc. (US) | 2015-05-07 | — | — | WO | disclosed |
| WO-2014144485-A9 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF BARRETT'S ESOPHAGUS AND GASTROESOPHAGEAL REFLUX DISEASE | Lumena Pharmaceuticals, Inc. (US) | 2015-01-15 | — | — | WO | disclosed |
| WO-2014144650-A2 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS AND INFLAMMATORY BOWEL DISEASE | Lumena Pharmaceuticals, Inc. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014144485-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF BARRETT'S ESOPHAGUS AND GASTROESOPHAGEAL REFLUX DISEASE | Lumena Pharmaceuticals, Inc. (US) | 2014-09-18 | — | — | WO | disclosed |
| EP-2770990-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE | Lumena Pharmaceuticals, Inc. (US) | 2014-09-03 | — | — | EP | disclosed |
| EP-2771003-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | Lumena Pharmaceuticals, Inc. (US) | 2014-09-03 | — | — | EP | disclosed |
| EP-2739286-A2 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PANCREATITIS | Lumena Pharmaceuticals, Inc. (US) | 2014-06-11 | — | — | EP | disclosed |
| WO-2013063512-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | LUMENA PHARMACEUTICALS, INC (US) | 2013-05-02 | — | — | WO | disclosed |
| WO-2013063526-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE | Lumena Pharmaceuticals, Inc. (US) | 2013-05-02 | — | — | WO | disclosed |
| EP-2575821-A2 | BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS | Satiogen Pharmaceuticals, Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| WO-2013020108-A2 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PANCREATITIS | Lumena Pharmaceuticals, Inc. (US) | 2013-02-07 | — | — | WO | disclosed |
| WO-2011150286-A2 | BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS | SATIOGEN PHARMACEUTICALS,INC. (US) | 2011-12-01 | — | — | WO | disclosed |